Bendamustine plus rituximab in newly‐diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO)
暂无分享,去创建一个
M. Béné | K. Laribi | V. Leblond | R. Le Calloch | S. Tricot | C. Dartigeas | J. Dupuis | J. Eveillard | D. Chaoui | S. Poulain | C. Herbaux | X. Roussel | L. Willems | Alix Baugier de Materre | F. Merabet | B. Bareau | D. Roos-Weil
[1] M. Dimopoulos,et al. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia , 2018, The New England journal of medicine.
[2] T. Habermann,et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia , 2018, Annals of hematology.
[3] G. Gaidano,et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia , 2014, Leukemia & lymphoma.
[4] M. Stauch,et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.
[5] S. Treon,et al. Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. , 2011, Clinical lymphoma, myeloma & leukemia.
[6] J. Crowley,et al. International prognostic scoring system for Waldenstrom macroglobulinemia. , 2009, Blood.